Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilutamide SCHEMBL12670 | 0.85 | AR (1.00) | ARLMNARAB9ASMN1; SMN2MEN1 | |
| Nilutamide SCHEMBL1462011 | 0.85 | AR (1.00) | ARLMNARAB9ASMN1; SMN2MEN1 | |
| Nilutamide SCHEMBL29351021 | 0.85 | AR (1.00) | ARLMNARAB9ASMN1; SMN2MEN1 | |
| Nilutamide SCHEMBL28562851 | 0.84 | AR (0.98) | ARLMNARAB9ASMN1; SMN2MEN1 | |
| Nilutamide SCHEMBL20695037 | 0.81 | AR (0.89) | ARLMNARAB9ASMN1; SMN2MEN1 | |
| Nilutamide SCHEMBL5579273 | 0.81 | AR (0.89) | ARLMNARAB9ASMN1; SMN2MEN1 | |
| SCHEMBL8407306 | 0.79 | AR (0.78) | ARLMNARAB9ASMN1; SMN2MEN1 | |
| SCHEMBL332500 | 0.78 | AR (0.73) | ARLMNARAB9ASMN1; SMN2MEN1 | |
| SCHEMBL10554935 | 0.78 | AR (0.73) | ARLMNARAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4025728 | 0.78 | AR (0.70) | ARLMNARAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710091-B2 | Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug | IPSEN PHARMA S.A.S. (FR) | 2014-04-29 | — | — | US | disclosed |
| EP-2419410-B1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA SAS (FR) | 2013-03-06 | — | — | EP | disclosed |
| US-20120083514-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2012-04-05 | — | — | US | disclosed |
| EP-2419410-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010119193-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083514-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | MKI67, CCND2, CCND1 | AR 1752/4885LMNA 2812/4885RAB9A 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.